More about our cookie policy.
HONG KONG – Singapore is Biofourmis Inc.’s newest destination for its Biovitals Sentinel platform to remotely monitor patients with COVID-19, with the country’s Ministry of Health (MOH) being the company’s last customer.
The platform monitors patients who are positive for COVID-1nine for early symptoms of deterioration, allowing healthcare professionals to interfere remotely. It is the newest device used by Biovitals, Biofourmis’s Boston-based artificial intelligence health analysis platform, which expects clinical exacerbation until nine o’clock at night. before an occasion occurs, allowing for early intervention.
The Biofourmis Everion biosensor, carried in the patient’s most sensitive arm, produces the knowledge to be analyzed across the platform. The biosensor, together with Biovitals Analytics, measures more than 20 biomarkers, adding temperature, blood oxygenation, central frequency, blood pulse waves, central frequency variability, breathing rate and period between beats.
“Singapore is the fifth largest country to deploy Biovitals Sentinel, which has already been deployed in Hong Kong, the United States, the United Kingdom and Australia,” BioWorld Kuldeep Singh Rajput, CEO of Biofourmis, told BioWorld Kuldeep Singh Rajput. “We started talks with the Ministry of Health in April, which resulted in a contract for the care of COVID-19 patients in the city.” Biofourmis also has a workplace in Lion City, as well as workplaces in Zurich and Bengaluru, India.
Clinical trials of the platform were conducted in Hong Kong in February. Biofourmis announced that the University of Hong Kong had decided for its remote monitoring and disease surveillance program a month later. The program monitored COVID-19 physiological biomarkers indicating deterioration in quarantined patients who were diagnosed or suspected of being inflamed with COVID-19. The platform is being used lately at various quarantine services in Hong Kong.
“The accuracy of the platform is achieved through the knowledge gathered to analyze how the disease manifests itself uniquely in each patient and create a signature profile, taking into account the [more than] 20 biomarkers measured across the platform. The key is to rely on classical physiological signals with other signals and parameters, such as cough samples».
Bioimportants Sentinel kits configured through the company in collaboration with the Singapore Ministry of Health come with the Everion biosensor, doctor board and a preloaded smartphone with the Bioimportants Sentinel patient app. The panels are tailor-made for easy remote monitoring and are set with critical thresholds to alert physical health professionals to abnormalities in a patient’s important signs.
Meanwhile, the patient-centered smartphone app synchronizes real-time knowledge and collects patient qualitative knowledge through questions about their symptoms and functional status. Biofourmis has worked with several agencies to translate the app into six other languages, adding simplified and classic Chinese, as well as Malay, Tamil and Bengali to satisfy the wishes of Singapore’s diverse population and a large number of foreign workers. The app has also been translated into Spanish for the US market in order to deal with the huge Spanish-speaking population.
In addition, the company has established a remote team that uses video and chat capabilities to provide remote technical support in multiple languages to help patients perceive how to use the app.
The personalized platform will be used in network care services established through the Ministry of Health for coVID-19 patients who are clinically well and no longer require acute care, as well as newly diagnosed patients with mild symptoms that do not require hospital care.
Facility fitness workers, located in locations such as Singapore Expo and Max Atria, will use the platform dashboard to remotely monitor important patient symptoms and receive alerts on their cell phones about the first symptoms of deterioration or significant physiological adjustments that may require medical attention. intervention.
The platform is also used in several swab isolation facilities to treat and control the symptoms of patients waiting for their results. Its ability to monitor patients remotely minimizes the exposure of frontline fitness care professionals to the virus, while at the same time providing real-time knowledge for a large number of patients.
Biofourmis’s hopes for the platform do not prevent monitoring of COVID-19 symptoms. Rajput also expects the device’s functions to monitor multiple biomarkers to be used to diagnose COVID-19, especially in asymptomatic patients. Meanwhile, the platform is being used through two drug manufacturers/researchers in clinical trials for their COVID-19 treatments, Rajput refused to provide additional details.
With an initial low number of instances and deaths, Singapore has recently noticed a new outbreak of COVID-19 in workers’ dormitories abroad. The city reported 51,531 cases of COVID-19 and 27 deaths as of July 30, according to Johns Hopkins University. Meanwhile, the number of global instances has exceeded 17 million.
The increasing number of global coVID-19 instances has led Biofourmis to look for more markets for the kit. “Lately we are in complex discussions with two governments in particular, and active discussions with other governments are also on the way,” Rajput said. He refused to provide additional details.
Meanwhile, Biofourmis aims to begin phase I trials “between July and August expired” for an as yet unnamed device that it is developing in conjunction with Chugai Pharmaceutical Co. Ltd. to measure pain grades in endometromia patients.
Enjoy a long-term policy to get the most comprehensive view of the market with BioWorld, BioWorld MedTech and BioWorld Asia in an easily accessible subscription.